Literature DB >> 29743236

IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53.

Bin Jiang1, Wentao Zhao1, Minggang Shi2, Jia Zhang1, Ai Chen1, Huanhuan Ma1, Muhammad Suleman1, Furong Lin1, Lin Zhou1, Jinyang Wang1, Yan Zhang1, Mengjue Liu1, Shixiong Wen1, Cong Ouyang1, Huihui Wang1, Xiumin Huang3, Huamin Zhou4, Qinxi Li5.   

Abstract

Resistance to apoptosis and uncontrolled proliferation are two hallmarks of cancer cells. p53 is crucial for apoptosis triggered by a broad range of stresses and a well-known gatekeeper for neoplastic transformation. Here we show that oncogenic IDH1 R132H/R132Q mutants robustly inhibit p53 expression and such an effect is attributed to 2-HG production. Mechanistically, 2-hydroxyglutarate (2-HG) stabilizes hypoxia-inducible factor-2α, which in turn activates the expression of miR-380-5p, a characterized microRNA against p53 expression. Rescue expression of p53 can inhibit the proliferation rate and impair the resistance of apoptosis induced by doxorubicin in IDH1 R132Q mouse embryonic fibroblast cells. Furthermore, p53 protein levels correlates negatively with IDH1 R132H levels in human glioma samples. Our results thus shed a new light on how p53 is down-regulated by 2-HG and suggests that impairment of p53-mediated apoptosis contributes to the tumorigenesis driven by IDH1 mutants.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  IDH1 mutant; brain tumor; cell metabolism; hypoxia-inducible factor (HIF); microRNA (miRNA); p53

Mesh:

Substances:

Year:  2018        PMID: 29743236      PMCID: PMC6016470          DOI: 10.1074/jbc.RA117.001385

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs.

Authors:  Christopher K Raymond; Brian S Roberts; Phillip Garrett-Engele; Lee P Lim; Jason M Johnson
Journal:  RNA       Date:  2005-11       Impact factor: 4.942

2.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

3.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

4.  Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.

Authors:  Mi Ran Kang; Min Sung Kim; Ji Eun Oh; Yoo Ri Kim; Sang Yong Song; Seong Il Seo; Ji Youl Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

5.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

Review 6.  The P53 pathway: what questions remain to be explored?

Authors:  A J Levine; W Hu; Z Feng
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

7.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

8.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

9.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

10.  Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

Authors:  Satoshi Inoue; Wanda Y Li; Alan Tseng; Isabel Beerman; Andrew J Elia; Sean C Bendall; François Lemonnier; Ken J Kron; David W Cescon; Zhenyue Hao; Evan F Lind; Naoya Takayama; Aline C Planello; Shu Yi Shen; Alan H Shih; Dana M Larsen; Qinxi Li; Bryan E Snow; Andrew Wakeham; Jillian Haight; Chiara Gorrini; Christian Bassi; Kelsie L Thu; Kiichi Murakami; Alisha R Elford; Takeshi Ueda; Kimberly Straley; Katharine E Yen; Gerry Melino; Luisa Cimmino; Iannis Aifantis; Ross L Levine; Daniel D De Carvalho; Mathieu Lupien; Derrick J Rossi; Garry P Nolan; Rob A Cairns; Tak W Mak
Journal:  Cancer Cell       Date:  2016-07-14       Impact factor: 31.743

View more
  8 in total

Review 1.  To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.

Authors:  Bharathan Bhavya; C R Anand; U K Madhusoodanan; P Rajalakshmi; K Krishnakumar; H V Easwer; A N Deepti; Srinivas Gopala
Journal:  Cell Mol Neurobiol       Date:  2019-09-04       Impact factor: 5.046

2.  Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma.

Authors:  Nasrin Shayanfar; Ali Zare-Mirzaie; Mahsa Mohammadpour; Ensieh Jafari; Amirhosein Mehrtash; Nikoo Emtiazi; Fatemeh Tajik
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-05       Impact factor: 4.322

Review 3.  IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives.

Authors:  Fabiana Crispo; Michele Pietrafesa; Valentina Condelli; Francesca Maddalena; Giuseppina Bruno; Annamaria Piscazzi; Alessandro Sgambato; Franca Esposito; Matteo Landriscina
Journal:  Molecules       Date:  2020-08-18       Impact factor: 4.411

Review 4.  2-Hydroxyglutarate in Cancer Cells.

Authors:  Petr Ježek
Journal:  Antioxid Redox Signal       Date:  2020-01-22       Impact factor: 7.468

Review 5.  Recent advances of IDH1 mutant inhibitor in cancer therapy.

Authors:  Wangqi Tian; Weitong Zhang; Yifan Wang; Ruyi Jin; Yuwei Wang; Hui Guo; Yuping Tang; Xiaojun Yao
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

Review 6.  IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.

Authors:  Sue Han; Yang Liu; Sabrina J Cai; Mingyu Qian; Jianyi Ding; Mioara Larion; Mark R Gilbert; Chunzhang Yang
Journal:  Br J Cancer       Date:  2020-04-15       Impact factor: 7.640

Review 7.  A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer.

Authors:  Yuqing Xiong; Yun Zhang; Shunbin Xiong; Abie E Williams-Villalobo
Journal:  Biology (Basel)       Date:  2020-09-11

Review 8.  Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer.

Authors:  Martina Godel; Giacomo Ortone; Dario Pasquale Anobile; Martina Pasino; Giulio Randazzo; Chiara Riganti; Joanna Kopecka
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.